
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by the clonal proliferation of Langerhans cells, and osseous involvement is the most frequent manifestation in pediatric patients. Although pulmonary involvement is recognized in LCH, respiratory presentations typically reflect direct pulmonary or airway disease rather than reversible obstructive symptoms. We report the case of a 4-year-old child with persistent, painful frontal swelling following minor trauma, which was initially presumed to be a post-traumatic hematoma. During the diagnostic course, the patient developed an asthma exacerbation that improved with bronchodilator and corticosteroid therapy. Imaging revealed a solitary osteolytic lesion of the frontal bone, and histopathological examination confirmed unifocal LCH. No clinical or chest radiographic evidence of pulmonary involvement was identified. This case underscored that persistent post-traumatic cranial swelling warrants imaging and histopathological evaluation, and highlights that the concurrent asthma exacerbation represents a temporal clinical overlap without proven causality.
Background: Anthracyclines are cornerstone agents in breast cancer chemotherapy. However, they can cause dose-dependent cardiotoxicity, potentially impairing long-term cardiac function. Beta-blockers have demonstrated cardioprotective effects. However, evidence regarding bisoprolol, particularly using comprehensive echocardiographic evaluations, remains limited. This study aimed to evaluate the cardioprotective effects of low-dose bisoprolol against anthracycline-induced subclinical cardiac dysfunction in patients with breast cancer.Methods: This triple-blind, randomized controlled trial was conducted in Isfahan, Iran, between January and December 2023. Eligible women with locally advanced breast cancer receiving anthracycline-based chemotherapy were randomized to bisoprolol (2.5 mg/day) or a placebo. Cardiac function was assessed at baseline, mid-treatment, and the end of treatment during a 6-month follow-up period. The evaluated echocardiographic parameters included left ventricular ejection fraction (LVEF), left ventricular end-diastolic and end-systolic dimensions (LVEDD, LVESD), left ventricular end-diastolic volume (LVEDV), global longitudinal strain (GLS), and tricuspid annular systolic excursion (TAPSE). Statistical analyses were performed using SPSS software (version 25.0). Continuous variables were analyzed using paired or independent-samples t tests, and categorical variables were analyzed using the Chi square test. Statistical significance was defined as P<0.05.Results: A total of 50 patients completed the trial (25 in the bisoprolol group and 25 in the placebo group). LVEF remained stable in both groups. Compared with the placebo group, bisoprolol demonstrated significantly more favorable structural and functional changes, including a reduction in LVEDD (mean change=-0.172 cm; 95% CI=-0.343 to -0.001; P=0.049), LVESD (mean change=-0.156 cm; 95% CI=-0.295 to -0.172; P=0.029), and LVEDV (mean change=-7.920 mL; 95% CI=-15.174 to -0.666; P=0.033); improved GLS (mean change=0.974; 95% CI=0.083 to 1.865; P=0.033); and better preserved TAPSE (mean change=0.168 cm; 95% CI=0.101 to 0.234; P<0.001).Conclusion: Prophylactic bisoprolol might attenuate early subclinical cardiotoxicity in patients with breast cancer receiving anthracyclines, primarily through the stabilization of LVEDV and a more favorable GLS trajectory. Iranian Registry of Clinical Trials: IRCT20130701013828N8
The study “Perception of Social Support in Brazilian Adult Patients with Epilepsy” evaluated 136 patients with chronic epilepsy, with a mean age of 45.5 years.
Background: Increased pyrimidine metabolism is characterized by dysregulation of the rate-limiting enzymes in this pathway, including uridine cytidine kinase 2 (UCK2), deoxythymidylate kinase (DTYMK), and cytidine triphosphate synthetase 1 (CTPS1). Emerging evidence highlighted the critical role of these enzymes in cancer progression. Methods: This cross-sectional study was conducted at Golestan University of Medical Sciences (Gorgan, Iran) in 2023. Initially, the Gene Expression database of Normal and Tumor tissue (GENT2) and the OncoDB database were checked to investigate the expression of these genes in esophageal cancer (EC) tissues. Subsequently, 34 pairs of newly diagnosed esophageal squamous cell carcinoma (ESCC) tissues and matched adjacent healthy tissues were collected. Real-time PCR was performed to measure the expression of these genes in the collected tissues. Statistical analyses were performed using SPSS version 22 and GraphPad Prism version 8. The Mann-Whitney test and the Wilcoxon matched-pairs signed-rank test were used to compare gene expression. P<0.05 was considered statistically significant.Results: The results demonstrated that CTPS1 (1.47 and 0.246-6.964, P=0.035) and DTYMK (1.62 and 0.733-5.278, P=0.009) expression levels in tumor tissue were higher than those in adjacent healthy tissues. The expression level of the UCK2 gene (1.32 and 0.278-3.834, P=0.052) was elevated in tumor tissues compared with surrounding non-tumor tissues. However, this difference was not statistically significant. Furthermore, DTYMK expression was significantly higher in females (3.73 and 1.505-11.313) than in males (0.81 and 0.213-1.624, P=0.007).Conclusion: CTPS1 and DTYMK were overexpressed in ESCC tissues compared with adjacent healthy tissue, which could provide valuable insights for the development of ESCC treatment strategies.
Background: Inflammatory cytokines are thought to contribute to the development of inhibitors against factor VIII (FVIII) in patients with severe hemophilia A (HA). In this study, we evaluated the association between plasma interleukin-6 (IL-6) levels and inhibitor development and plasmablast frequencies in severe HA patients.Methods: This case–control study included 32 severe HA patients, who were admitted to the Comprehensive Hemophilia Center affiliated with Shiraz University of Medical Sciences between January and December 2022. The studied groups comprised eight severe HA patients with inhibitors, 24 without inhibitors, and 24 age- and sex-matched healthy controls. Plasma IL-6 levels were measured using the enzyme-linked immunosorbent assay (ELISA) and compared between studied groups using the Student’s t test (for two groups) and ANOVA (for more than 2 groups). Correlation between IL-6 levels and inhibitor titers, as well as plasmablast frequencies, was assessed using Spearman’s correlation test. Results: Plasma IL-6 levels were higher in HA patients than healthy controls; however, the difference was not statistically significant (P=0.197). Patients with inhibitors exhibited significantly elevated IL-6 levels compared with both inhibitor-negative HA patients (*P=0.001) and healthy controls (*P=0.001). Moreover, plasma IL-6 levels correlated significantly with inhibitor titers (r=0.393, *P=0.026) but not plasmablast frequencies (r=0.173, P=0.208). Receiver operating characteristic (ROC) curve analysis indicated that elevated IL-6 is a specific but moderately sensitive marker for inhibitor status in severe HA patients (sensitivity=62.5%, and specificity=87.5%, *P=0.027). Conclusion: This study suggests that plasma IL-6 levels may serve as a fair-to-good immunological marker for predicting inhibitor development in severe HA patients.